Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 8 pages · English
Earlier from Acrux
- FDA clears regulatory pathway for Female Testosterone MDTS
- Acrux has received $1.977m RDTI rebate for FY26
- FY26 Annual Report and Appendix 4E
- Investor Presentation - Female Testosterone for HSDD
- Update - Licensing Lenzetto for Australia for AUD5.4m
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux